OctoPlus N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
11 mrt 2008 - 17:59
Statutaire naam
OctoPlus N.V.
Titel
OctoPlus announces publications of Phase I Locteron results in the Journal of Interferon and Cytokine Research
Bericht
OctoPlus N.V. (“OctoPlus” or “the Company”) (Euronext: OCTO), the drug delivery and development company, announces today the publication of results from its Phase I study with Locteron®, its controlled-release formulation of alfa interferon for the treatment of chronic hepatitis C, in the current issue of the Journal of Interferon & Cytokine Research. In the randomised Phase I trial, the administration of Locteron demonstrated bioactivity over a two-week period and resulted in flu-like symptoms that were less frequent, milder and of a shorter duration in a head-to-head comparison with PEG-Intron®, the standard of care used as the control arm in the study.
OctoPlus also announces that updated results from its SELECT-1 Phase IIa trial of Locteron have been selected for presentation at the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL) conference April 23-27, 2008 in Milan, Italy.
Datum laatste update: 31 oktober 2025